Curated News
By: NewsRamp Editorial Staff
October 21, 2025
Oncotelic's 20nm Nanoparticle Tech Boosts Cancer Drug Delivery to 100%
TLDR
- Oncotelic's 20nm Deciparticle technology provides competitive advantage by achieving full bioavailability of Everolimus, maximizing tumor targeting compared to 10% absorption with oral formulations.
- Oncotelic's proprietary 20nm nanoparticle platform works by optimizing particle size for enhanced drug delivery, using intravenous administration to improve tumor targeting and therapeutic efficacy.
- This technology makes tomorrow better by improving cancer treatment outcomes through targeted drug delivery that minimizes side effects and enhances patient quality of life.
- Oncotelic's 20nm nanoparticles achieve what oral formulations cannot, delivering 100% bioavailability of cancer drugs directly to tumors through precise size optimization.
Impact - Why it Matters
This development matters because it addresses one of the most persistent challenges in cancer treatment: delivering therapeutic agents effectively to tumors while minimizing damage to healthy tissues. Current oral cancer medications often have poor bioavailability, meaning patients receive only a fraction of the intended dose while experiencing significant side effects. Oncotelic's nanoparticle technology achieving 100% bioavailability could dramatically improve treatment efficacy and reduce adverse effects, potentially transforming patient outcomes. For the millions affected by breast cancer worldwide, this represents hope for more effective, targeted therapies that could extend survival and improve quality of life during treatment. The accelerated development platform also means these innovations could reach patients faster than traditional drug development timelines would allow.
Summary
Oncotelic Therapeutics Inc. (OTCQB: OTLC) has achieved a significant milestone with the commencement of its Sapu003 Phase 1 clinical trial, following Australian HREC approval that validates the company's proprietary 20nm nanoparticle technology. This breakthrough represents a major advancement in precision nanomedicine for breast cancer treatment, specifically through enhanced drug delivery systems. The core innovation lies in Oncotelic's Deciparticle(TM) platform, which enables intravenous delivery of Everolimus (marketed as Afinitor(R)) with remarkable 100% bioavailability compared to the mere 10% absorption rate of conventional oral formulations. This dramatic improvement in drug delivery efficiency directly translates to superior tumor targeting and therapeutic efficacy, potentially revolutionizing cancer treatment outcomes.
The strategic partnership with Medicilon represents another critical component of Oncotelic's accelerated development strategy, supporting up to 20 IND projects through their rapid IND platform. This collaboration enables multiple Deciparticle(TM) drug candidates to reach clinical testing quickly, significantly shortening development timelines across the company's pipeline. The technology's foundation rests on the critical importance of particle size in targeted drug delivery, addressing fundamental challenges in oncology where conventional chemotherapy often exposes healthy tissues to cytotoxic agents and oral targeted therapies frequently fail to achieve therapeutic concentrations at tumor sites. The BioMedWire coverage highlights how nanomedicine offers promising solutions to these longstanding treatment limitations.
As part of the broader IBN Dynamic Brand Portfolio, BioMedWire provides specialized communications focusing on biotechnology and biomedical sciences, ensuring this groundbreaking development reaches investors, medical professionals, and the broader healthcare community. The successful validation of Oncotelic's 20nm nanoparticle technology not only marks progress for Sapu003 specifically but establishes a platform technology with potential applications across multiple cancer types and therapeutic areas. This advancement represents a significant step forward in the ongoing evolution of precision medicine and targeted cancer therapies, offering hope for improved treatment outcomes and reduced side effects for patients battling breast cancer and potentially other malignancies.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's 20nm Nanoparticle Tech Boosts Cancer Drug Delivery to 100%
